Seeplex® H.pylori ClaR ACE Detection

Helicobacter Pylori, a major cause of chronic gastritis, is strongly associated with the development of gastric and duodenal ulcers and has been linked with gastric adenocarcinoma and B-cell mucosa-associated lymphoid tissue lymphoma. Current treatment of H. pylori infection consists of a triple or quadruple regimen that includes antibiotics and a proton inhibitor, such as amoxicillin and clarithromycin. Among these, the presence of clarithromycin-resistant H. pylori has been found, which has presented a serious obstacle to the treatment of H. pylori using clarithromycin. Thus, the detection of clarithromycin-resistant H. pylori is needed to increase the efficiency of the treatment and to prescribe other antibiotics by diagnosing the presence of clarithromycin-resistant H. pylori before treatment with antibiotics. Most clarithromycin- resistant H. pylori have point mutation at the 2142 and 2143 base sequences of the 23S rRNA gene, and exist as A2142G and A2143G, respectively. Seeplex® H. pylori-ClaR ACE Detection is developed to detect these two kinds of point mutations specifically using DPO™ technology.

Direct examination of gastric biopsy tissue without going through bacterial culture
Simultaneous identification of H. pylori and two point mutations (A2143G & A2142G), which cause clarithromycin
  resistance without culture
Applicable for Auto-capillary Electrophoresis instruments
A single round PCR process reduces the carryover contamination risk, and 8-MOP, which is included in product,
  eliminates the contamination risk from PCR products
Accurate system for result interpretation included Internal Control and Positive Control

H.pylori
A2142G
A2143G

Gastric biopsy